| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22021 |
| Drug | Ciltacabtagene autoleucel |
| Brand | Carvykti® |
| Indication | For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
| Assessment Process | |
| Rapid review commissioned | 11/04/2022 |
| Rapid review completed | 12/05/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cilta-cel (ciltacabtagene autoleucel) compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/05/2022 |
| Pre-submission consultation with Applicant | 12/07/2022 |
| Full submission received from Applicant | 30/11/2022 |
| Preliminary review sent to Applicant | 30/05/2023 |
| NCPE assessment re-commenced | 27/06/2023 |
| Factual accuracy sent to Applicant | 04/09/2023 |
| NCPE assessment re-commenced | 12/09/2023 |
| NCPE assessment completed | 27/09/2023 |
| NCPE assessment outcome | The NCPE recommends that cilta-cel not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
